Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07091617 · ClinicalTrials.gov registry record · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
A NA study of Miscellaneous Neoplasm, NOS and Non-Neoplastic Condition, Nos, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- NA
- Development phase
- 535
- Enrollment target
- 20
- Study locations
NCT07091617 is a NA study of Miscellaneous Neoplasm, NOS and Non-Neoplastic Condition, Nos that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 535 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT07091617, a NA study of Miscellaneous Neoplasm, NOS and Non-Neoplastic Condition, Nos, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- NA
- Development phase
- 535 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares the use of a digital chatbot enabled intervention to standard remote genetic services for increasing uptake of genetic counseling and testing among adolescents and young adult (AYA) cancer patients. Genetic testing for cancer predisposition syndromes has become standard evidence-based practice and can inform enhanced screening and risk reducing measures to reduce cancer morbidity and mortality. Despite this, many AYAs are not receiving recommended genetic counseling and testing. Offering remote telehealth services can address access barriers and chatbots and texting interventions could enhance patient outcomes and reduce provider and staff time. The use of a digital chatbot enabled intervention may be equally as effective as standard remote genetic services in AYA cancer patients undergoing genetic testing.
Conditions Studied
Interventions
- OTHER Educational Intervention
- OTHER Genetic Testing
- OTHER Internet-Based Intervention
- OTHER Telemedicine
Study Locations (20)
California
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Mercy Cancer Center - Carmichael - Carmichael
- Mercy San Juan Medical Center - Carmichael
- Mercy Cancer Center - Elk Grove - Elk Grove
- Mercy Cancer Center - Merced
- Providence Queen of The Valley - Napa
- Mercy Cancer Center - Rocklin - Rocklin
- Mercy Cancer Center - Sacramento - Sacramento
- Pacific Central Coast Health Center-San Luis Obispo - San Luis Obispo
- Mission Hope Medical Oncology - Santa Maria - Santa Maria
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CARTI Cancer Center - Little Rock
Arizona
- Cancer Center at Saint Joseph's - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2025-12-10 |
| Est. Completion | 2029-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07091617
The ClinicalTrials.gov registry entry for NCT07091617 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 535 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Miscellaneous Neoplasm, NOS appearing as the primary indexed condition, and to 4 interventions - of which Educational Intervention is the first listed.
NCT07091617 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alaska, Arkansas.
Frequently Asked Questions
What is clinical trial NCT07091617 about?
NCT07091617 is a clinical study titled "Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer". This phase III trial compares the use of a digital chatbot enabled intervention to standard remote genetic services for increasing uptake of genetic counseling and testing among adolescents and young adult (AYA) cancer patients. Genetic testing for cancer predisposition syndromes has become standard...
What is the current status of trial NCT07091617?
This trial is currently recruiting. It is a NA study. The enrollment target is 535 participants. The study started on 2025-12-10. Estimated completion is 2029-04-30.
What conditions does trial NCT07091617 study?
This clinical trial studies the following conditions: Miscellaneous Neoplasm, NOS, Non-Neoplastic Condition, Nos.
What interventions are being tested in trial NCT07091617?
The interventions under investigation include: Educational Intervention (OTHER), Genetic Testing (OTHER), Internet-Based Intervention (OTHER), Telemedicine (OTHER).
Who is sponsoring clinical trial NCT07091617?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07091617 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Miscellaneous Neoplasm, NOS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.